News | AUGS

DEP-20210315-Urogyne-ElizabethMueller_Individual_6 copy

President's Perspective: Looking Ahead and Hoping for A Return to a Normal 2022

Nov 16, 2021 12:56 PM

The last month has brought to mind a phrase from American critic, Dorothy Parker, “What fresh hell is this!” Who of us could have imagined this ending to 2021 that started with such hope with the COVID-19 vaccine? I, like most of you, am setting realistic goals for this new year and learning to embrace uncertainty. To help us continue navigating during this difficult time, AUGS is also evolving its programs and activities.

President's Perspective: Seeking Your Nominations for the Raymond E. Lee Lectureship

Nov 16, 2021 12:56 PM

While PFD Week 2021 is only 30 days past, AUGS volunteers and staff are already starting to prepare for our AUGS/IUGA 2022 Joint Scientific Meeting in June. An important part of our meeting is the recognition of our outstanding teachers/surgeons and research coordinators.

Consensus Statement: Vaginal Energy-Based Devices (May 2020)

This clinical consensus statement on vaginal energy-based devices (EBDs) reflects statements drafted by content experts from the American Urogynecologic Society’s EBD writing group.

Frequently Asked Questions by Providers Mid-urethral Slings for Stress Urinary Incontinence

The purpose of this Frequently Asked Questions document is to provide factual information for healthcare providers who are involved in the care of women considering such treatment.

Clinical Guidance Document: Pregnancy in Women With Prior Treatments for Pelvic Floor Disorders

Although the peak incidence of surgery for pelvic floor disorders does not occur until after menopause, an increasing number of younger women are seeking treatment for these problems. Whereas most surgeons would recommend delaying surgery until the completion of childbearing, published cases and case series address outcomes after subsequent pregnancies in women who have been treated for urinary incontinence and pelvic organ prolapse.

Position Statement on Restriction of Surgical Options for Pelvic Floor Disorders

In July 2011, the U.S. Food and Drug Administration (FDA) released a white paper [1] and safety communication [2] on the safety and effectiveness of transvaginal placement of surgical mesh for pelvic organ prolapse. Since then, some state medical organizations, healthcare systems, and insurance companies have considered, or adopted, complete restrictions on the use of transvaginal mesh for pelvic organ prolapse or stress urinary incontinence.

Frequently Asked Questions by Patients Mid-urethral Slings for Stress Urinary Incontinence

A summary of patient FAQs for mid-urethral slings.

Midurethral Sling Supplemental Information Checklist

In order to optimize the quality and consistency of information reviewed with patients, and make it easier for health care providers to document this information exchange, AUGS has developed this Supplemental Information Checklist.

Microscopic Hematuria as a Screening Tool for Urologic Malignancies in Women

Most causes of microscopic hematuria (MH) are benign but may indicate an underlying malignancy. Current MH evaluation guidelines are reflective of male urologic malignancy risks. The objective of this systematic review was to evaluate whether the finding of MH predicts subsequent urologic malignancy in women.

Joint Report on Terminology for Surgical Procedures to Treat Pelvic Organ Prolapse

Surgeries for pelvic organ prolapse (POP) are common, but standardization of surgical terms is needed to improve the quality of investigation and clinical care around these procedures.